ALLOPURINOL - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for allopurinol and what is the scope of patent protection?
Allopurinol
is the generic ingredient in six branded drugs marketed by Accord Hlthcare, Aiping Pharm Inc, Chartwell, Endo Operations, Harman Finochem, Hetero Labs Ltd V, Indoco, Ipca Labs Ltd, Lupin Ltd, Mutual Pharm, Mylan, Northstar Hlthcare, Puracap Pharm, Purepac Pharm, Sandoz, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, Unichem, Watson Labs, Zydus Pharms, Abbott, Dr Reddys La, Casper Pharma Llc, Gland Pharma Ltd, Hikma, and Ironwood Pharms Inc, and is included in thirty-six NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.There are twenty-two drug master file entries for allopurinol. Forty-three suppliers are listed for this compound.
Summary for ALLOPURINOL
US Patents: | 9 |
Tradenames: | 6 |
Applicants: | 27 |
NDAs: | 36 |
Drug Master File Entries: | 22 |
Finished Product Suppliers / Packagers: | 43 |
Raw Ingredient (Bulk) Api Vendors: | 274 |
Clinical Trials: | 222 |
Patent Applications: | 7,833 |
Drug Prices: | Drug price trends for ALLOPURINOL |
Drug Sales Revenues: | Drug sales revenues for ALLOPURINOL |
What excipients (inactive ingredients) are in ALLOPURINOL? | ALLOPURINOL excipients list |
DailyMed Link: | ALLOPURINOL at DailyMed |
Recent Clinical Trials for ALLOPURINOL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Urica Therapeutics Inc. | Phase 1/Phase 2 |
Eli Lilly and Company | Phase 2 |
Dana-Farber Cancer Institute | Phase 2 |
Pharmacology for ALLOPURINOL
Drug Class | Xanthine Oxidase Inhibitor |
Mechanism of Action | Xanthine Oxidase Inhibitors |
Medical Subject Heading (MeSH) Categories for ALLOPURINOL
Anatomical Therapeutic Chemical (ATC) Classes for ALLOPURINOL
US Patents and Regulatory Information for ALLOPURINOL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Harman Finochem | ALLOPURINOL | allopurinol | TABLET;ORAL | 214443-002 | Mar 7, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Watson Labs | ALLOPURINOL | allopurinol | TABLET;ORAL | 018877-001 | Sep 28, 1984 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Watson Labs | ALLOPURINOL | allopurinol | TABLET;ORAL | 018785-002 | Sep 28, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALLOPURINOL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbott | LOPURIN | allopurinol | TABLET;ORAL | 018297-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Casper Pharma Llc | ZYLOPRIM | allopurinol | TABLET;ORAL | 016084-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Casper Pharma Llc | ZYLOPRIM | allopurinol | TABLET;ORAL | 016084-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.